ANI Pharmaceuticals (ANIP)

[Just the facts maam]

With all the focus of discussion surrounding the CG Oncology litigation. I overlooked the following in ANIP Q1 10-Q filing.

Research and development expenses increased from $5.9 million to $10.5 million, an increase of $4.6 million or 77.4%, primarily due to expenses related to a FDA filing fee for a 505(b)(2) for one product of approximately $2.0 million, and a higher level of activity associated with ongoing and new projects in the three months ended March 31, 2024.

No mention of it whatsoever in the press release or the in the earnings related conference call.

It is likely for the first FDA approved Oral Liquid Composition Of Terazosin, which is the first patent Novitium received and is patent protected to February 1, 2041.

Maybe ANIP is waiting for confirmation of FDA acceptance of the application before announcing it, which they should have by now.

If all goes well, it should be approved in 2024 Q4 or 2025 Q1.

Obviously, this not calculated into ANIP's current PPS.